Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
19.02
-0.25 (-1.30%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cartesian Therapeutics Revenue
Cartesian Therapeutics had revenue of $387.00K in the quarter ending September 30, 2024, a decrease of -94.09%. This brings the company's revenue in the last twelve months to $47.94M, down -62.40% year-over-year. In the year 2023, Cartesian Therapeutics had annual revenue of $26.00M, down -76.53%.
Revenue (ttm)
$47.94M
Revenue Growth
-62.40%
P/S Ratio
4.86
Revenue / Employee
$1,261,526
Employees
38
Market Cap
489.30M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 26.00M | -84.77M | -76.53% |
Dec 31, 2022 | 110.78M | 25.70M | 30.21% |
Dec 31, 2021 | 85.08M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRNAC News
- 3 days ago - Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 18 days ago - Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial - GlobeNewsWire
- 4 weeks ago - Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit - GlobeNewsWire
- 5 weeks ago - Cartesian Therapeutics: Uncertainty Remains - Seeking Alpha
- 2 months ago - Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting - GlobeNewsWire
- 3 months ago - Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results - Seeking Alpha
- 3 months ago - Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewsWire
- 3 months ago - Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 - GlobeNewsWire